Literature DB >> 21768087

c-Cbl and Cbl-b ligases mediate 17-allylaminodemethoxygeldanamycin-induced degradation of autophosphorylated Flt3 kinase with internal tandem duplication through the ubiquitin proteasome pathway.

Gaku Oshikawa1, Toshikage Nagao, Nan Wu, Tetsuya Kurosu, Osamu Miura.   

Abstract

The class III receptor-tyrosine kinase Flt3 regulates normal hematopoiesis. An internal tandem duplication (ITD) in the juxtamembrane domain of Flt3 (Flt3-ITD) contributes to transformation and is associated with poor prognosis in acute myeloid leukemia. Here, we demonstrate that, as compared with wild-type Flt3 (Flt3-WT), Flt3-ITD more rapidly undergoes degradation through the proteasomal and lysosomal pathways in model hematopoietic 32D cells and in human leukemic MV4-11 cells. The Hsp90 inhibitor 17-allylaminodemethoxygeldanamycin (17-AAG) preferentially induced the polyubiquitination and proteasomal degradation of Flt3-ITD autophosphorylated on Tyr-591 in these cells. The E3 ubiquitin ligases c-Cbl and to a lesser extent Cbl-b facilitated at least partly Lys-48-linked polyubiquitination of autophosphorylated Flt3-ITD when coexpressed in 293T cells. Moreover, c-Cbl and Cbl-b facilitated degradation of Flt3-ITD in 293T cells and significantly enhanced the 17-AAG-induced decline in autophosphorylated Flt3-ITD. The enhancement of Flt3-ITD degradation was also observed in 32D cells inducibly overexpressing c-Cbl or Cbl-b. Furthermore, overexpression of loss-of-function mutants of both c-Cbl (c-Cbl-R420Q) and Cbl-b (Cbl-b-C373A) together in 32D cells retarded the degradation of autophosphorylated Flt3-ITD and significantly inhibited the 17-AAG-induced degradation of Flt3-ITD to confer the resistance to cytotoxicity of 17-AAG on these cells. These results suggest that c-Cbl as well as Cbl-b may play important roles in Hsp90 inhibitor-induced degradation of Flt3-ITD through the ubiquitin proteasome system and in regulation of the basal expression level of Flt3-ITD in leukemic cells.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21768087      PMCID: PMC3162385          DOI: 10.1074/jbc.M111.232348

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  46 in total

1.  WW domain HECT E3s target Cbl RING finger E3s for proteasomal degradation.

Authors:  Alessandra Magnifico; Seth Ettenberg; Cuihong Yang; Jennifer Mariano; Swati Tiwari; Shengyun Fang; Stan Lipkowitz; Allan M Weissman
Journal:  J Biol Chem       Date:  2003-08-07       Impact factor: 5.157

Review 2.  Retrovirus-mediated gene transfer and expression cloning: powerful tools in functional genomics.

Authors:  Toshio Kitamura; Yuko Koshino; Fumi Shibata; Toshihiko Oki; Hideaki Nakajima; Tetsuya Nosaka; Hidetoshi Kumagai
Journal:  Exp Hematol       Date:  2003-11       Impact factor: 3.084

3.  Parkin mediates nonclassical, proteasomal-independent ubiquitination of synphilin-1: implications for Lewy body formation.

Authors:  Kah Leong Lim; Katherine C M Chew; Jeanne M M Tan; Cheng Wang; Kenny K K Chung; Yi Zhang; Yuji Tanaka; Wanli Smith; Simone Engelender; Christopher A Ross; Valina L Dawson; Ted M Dawson
Journal:  J Neurosci       Date:  2005-02-23       Impact factor: 6.167

4.  Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3.

Authors:  Prince George; Purva Bali; Srinivas Annavarapu; Anna Scuto; Warren Fiskus; Fei Guo; Celia Sigua; Gautam Sondarva; Lynn Moscinski; Peter Atadja; Kapil Bhalla
Journal:  Blood       Date:  2004-10-28       Impact factor: 22.113

5.  Superior activity of the combination of histone deacetylase inhibitor LAQ824 and the FLT-3 kinase inhibitor PKC412 against human acute myelogenous leukemia cells with mutant FLT-3.

Authors:  Purva Bali; Prince George; Pamela Cohen; Jianguo Tao; Fei Guo; Celia Sigua; Anasuya Vishvanath; Anna Scuto; Srinivas Annavarapu; Warren Fiskus; Lynn Moscinski; Peter Atadja; Kapil Bhalla
Journal:  Clin Cancer Res       Date:  2004-08-01       Impact factor: 12.531

6.  Selective apoptosis of tandemly duplicated FLT3-transformed leukemia cells by Hsp90 inhibitors.

Authors:  Y Minami; H Kiyoi; Y Yamamoto; K Yamamoto; R Ueda; H Saito; T Naoe
Journal:  Leukemia       Date:  2002-08       Impact factor: 11.528

7.  Cbl-b interacts with ubiquitinated proteins; differential functions of the UBA domains of c-Cbl and Cbl-b.

Authors:  Gareth C Davies; Seth A Ettenberg; Ashley O Coats; Mark Mussante; Sarangan Ravichandran; Jack Collins; Marion M Nau; Stan Lipkowitz
Journal:  Oncogene       Date:  2004-09-16       Impact factor: 9.867

8.  Inactivation of erythropoietin receptor function by point mutations in a region having homology with other cytokine receptors.

Authors:  O Miura; J L Cleveland; J N Ihle
Journal:  Mol Cell Biol       Date:  1993-03       Impact factor: 4.272

9.  Cotreatment with 17-allylamino-demethoxygeldanamycin and FLT-3 kinase inhibitor PKC412 is highly effective against human acute myelogenous leukemia cells with mutant FLT-3.

Authors:  Prince George; Purva Bali; Pamela Cohen; Jianguo Tao; Fei Guo; Celia Sigua; Anasuya Vishvanath; Warren Fiskus; Anna Scuto; Srinivas Annavarapu; Lynn Moscinski; Kapil Bhalla
Journal:  Cancer Res       Date:  2004-05-15       Impact factor: 12.701

10.  FLT3 mutations in acute myeloid leukemia cell lines.

Authors:  H Quentmeier; J Reinhardt; M Zaborski; H G Drexler
Journal:  Leukemia       Date:  2003-01       Impact factor: 11.528

View more
  23 in total

1.  Adaptation to TKI Treatment Reactivates ERK Signaling in Tyrosine Kinase-Driven Leukemias and Other Malignancies.

Authors:  J Kyle Bruner; Hayley S Ma; Li Li; Alice Can Ran Qin; Michelle A Rudek; Richard J Jones; Mark J Levis; Keith W Pratz; Christine A Pratilas; Donald Small
Journal:  Cancer Res       Date:  2017-09-18       Impact factor: 12.701

2.  E3 ubiquitin ligase Cbl-b activates the p53 pathway by targeting Siva1, a negative regulator of ARF, in FLT3 inhibitor-resistant acute myeloid leukemia.

Authors:  I-K Park; W Blum; S D Baker; M A Caligiuri
Journal:  Leukemia       Date:  2016-10-24       Impact factor: 11.528

Review 3.  E3 ubiquitin ligase Cbl-b in innate and adaptive immunity.

Authors:  Qingjun Liu; Hong Zhou; Wallace Y Langdon; Jian Zhang
Journal:  Cell Cycle       Date:  2014-05-14       Impact factor: 4.534

4.  Molecular mechanisms for enhancement of stromal cell-derived factor 1-induced chemotaxis by platelet endothelial cell adhesion molecule 1 (PECAM-1).

Authors:  Yoshihiro Umezawa; Hiroki Akiyama; Keigo Okada; Shinya Ishida; Ayako Nogami; Gaku Oshikawa; Tetsuya Kurosu; Osamu Miura
Journal:  J Biol Chem       Date:  2017-10-03       Impact factor: 5.157

5.  PECAM-1 is involved in BCR/ABL signaling and may downregulate imatinib-induced apoptosis of Philadelphia chromosome-positive leukemia cells.

Authors:  Nan Wu; Tetsuya Kurosu; Gaku Oshikawa; Toshikage Nagao; Osamu Miura
Journal:  Int J Oncol       Date:  2012-12-06       Impact factor: 5.650

6.  The oral HDAC inhibitor pracinostat (SB939) is efficacious and synergistic with the JAK2 inhibitor pacritinib (SB1518) in preclinical models of AML.

Authors:  V Novotny-Diermayr; S Hart; K C Goh; A Cheong; L-C Ong; H Hentze; M K Pasha; R Jayaraman; K Ethirajulu; J M Wood
Journal:  Blood Cancer J       Date:  2012-05-04       Impact factor: 11.037

7.  DNA damage stress and inhibition of Jak2-V617F cause its degradation and synergistically induce apoptosis through activation of GSK3β.

Authors:  Toshikage Nagao; Gaku Oshikawa; Nan Wu; Tetsuya Kurosu; Osamu Miura
Journal:  PLoS One       Date:  2011-11-08       Impact factor: 3.240

8.  FLT3-ITD confers resistance to the PI3K/Akt pathway inhibitors by protecting the mTOR/4EBP1/Mcl-1 pathway through STAT5 activation in acute myeloid leukemia.

Authors:  Ayako Nogami; Gaku Oshikawa; Keigo Okada; Shusaku Fukutake; Yoshihiro Umezawa; Toshikage Nagao; Tetsuya Kurosu; Osamu Miura
Journal:  Oncotarget       Date:  2015-04-20

9.  Inhibition of USP10 induces degradation of oncogenic FLT3.

Authors:  Ellen L Weisberg; Nathan J Schauer; Jing Yang; Ilaria Lamberto; Laura Doherty; Shruti Bhatt; Atsushi Nonami; Chengcheng Meng; Anthony Letai; Renee Wright; Hong Tiv; Prafulla C Gokhale; Maria Stella Ritorto; Virginia De Cesare; Matthias Trost; Alexandra Christodoulou; Amanda Christie; David M Weinstock; Sophia Adamia; Richard Stone; Dharminder Chauhan; Kenneth C Anderson; Hyuk-Soo Seo; Sirano Dhe-Paganon; Martin Sattler; Nathanael S Gray; James D Griffin; Sara J Buhrlage
Journal:  Nat Chem Biol       Date:  2017-10-02       Impact factor: 15.040

10.  Ubiquitin ligase Cbl-b is involved in icotinib (BPI-2009H)-induced apoptosis and G1 phase arrest of EGFR mutation-positive non-small-cell lung cancer.

Authors:  Xiaodong Mu; Ye Zhang; Xiujuan Qu; Kezuo Hou; Jian Kang; Xuejun Hu; Yunpeng Liu
Journal:  Biomed Res Int       Date:  2013-03-19       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.